Claims
- 1. A pharmaceutical combination comprising at least one active compound of formula (I):
- 2. The pharmaceutical combination according to claim 1, wherein the Bcr-Abl tyrosine kinase inhibitor is imatinib mesylate (STI-571).
- 3. The pharmaceutical combination according to claim 2, wherein R is H.
- 4. The pharmaceutical combination according to claim 2, wherein B is cytosine.
- 5. The pharmaceutical combination according to claim 2, wherein R is H and B is cytosine.
- 6. The pharmaceutical combination according to claim 2, wherein B is 5-fluorocytosine.
- 7. The pharmaceutical combination according to claim 2, wherein the compound of formula I is (−)-β-L-Dioxolane-Cytidine (β-L-OddC).
- 8. The pharmaceutical combination according to claim 2, wherein the compound of formula I is (−)-β-Dioxolane-5-fluoro-Cytidine (5-FddC).
- 9. The pharmaceutical combination according to claim 2, wherein the compound of formula I is substantially in the form of the (−) enantiomer.
- 10. The pharmaceutical combination according to claim 2, wherein said compound of formula (I) is at least 97% free of the corresponding (+) enantiomer.
- 11. The pharmaceutical combination according to claim 2 wherein the compound of formula (I) is β-L-OddC and the Bcr-Abl tyrosine kinase inhibitor is imatinib mesylate (STI-571).
- 12. A pharmaceutical combination according to claim 2 wherein the compound of formula (I) and imatinib mesylate (STI-571) are present in a ratio between about 1:50 to about 50:1.
- 13. A pharmaceutical combination according to claim 2 wherein the compound of formula (I) and imatinib mesylate (STI-571) are present in a ratio between about 1:20 to about 20:1.
- 14. A pharmaceutical combination comprising at least one active compound of formula (I):
- 15. A method of treating a patient having leukemia comprising administering to said patient a therapeutically effective amount of a compound of formula I:
- 16. A method of treating a patient having leukemia according to claim 15 and wherein the ratio of the compound of formula (I) and the Bcr-Abl tyrosine kinase inhibitor is 1:250 to 250:1.
- 17. The method according to claim 15, wherein the step of administering comprises administering to a patient with acute myelogenous leukemia and chronic myelogenous leukemia.
- 18. The method according to claim 15, wherein the step of administering comprises administering to a patient with chronic myelogenous leukemia in blastic phase.
- 19. The method according to claim 15, wherein the step of administering comprises administering to a patient with refractory/relapsed leukemia.
- 20. The method according to claim 15, wherein the step of administering comprises administering to a patient with refractory/relapsed leukemia and which has been previously treated with imatinib mesylate (STI-571).
- 21. The method according to claim 15, wherein the step of administering comprises administering to a patient with refractory/relapsed leukemia and which has been previously treated with imatinib mesylate (STI-571) and is resistant to imatinib mesylate (STI-571).
- 22. The method according to claim 15, wherein the step of administering comprises administering to a patient with refractory/relapsed leukemia and which has been previously treated with imatinib mesylate (STI-571) wherein the compound of formula (I) is β-L-OddC and the Bcr-Abl tyrosine kinase inhibitor is imatinib mesylate (STI-571).
- 23. The method according to claim 15, wherein the step of administering comprises administering to a patient with refractory/relapsed leukemia and which has been previously treated with imatinib mesylate (STI-571) and wherein the compound of formula (I) is β-L-OddC and the Bcr-Abl tyrosine kinase inhibitor is imatinib mesylate (STI-571) and said combination is a synergistic combination.
- 24. A method of treating a patient having cancer, other than leukemia, comprising administering to said patient a therapeutically effective amount of a compound of formula I:
- 25. A pharmaceutical composition comprising a pharmaceutical combination according to claim 1 and at least one pharmaceutically acceptable carrier or excipient.
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Application No. 60/431,196, filed Dec. 6, 2002, which is expressly incorporated by reference herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60431196 |
Dec 2002 |
US |